NIVOLUMAB AND CABOZANTINIB MORE EFFECTIVE THAN EVEROLIMUS FOR RENAL CELL CANCER PATIENTS
@ Nivolumab, a cancer drug that works by improving body*s immune system response to cancer cells, has been found more effective for kidney cancer patients compared to standard therapy using everolimus .// In two separate research trials, Nivolumab and cabozantinib have been more successful for kidney cancer patients compared to standard treatment option .// ©Opdivo belongs to a group of drugs termed as immune checkpoint inhibitors .//
@ Opdivo is currently used for treatment of advanced skin cancer and lung cancer .// The research involving use of Nivolumab had 821 patients ©suffering from advanced stage kidney cancer .// The drug Nivolumab improves body*s immune system to deal with cancer cells .//
@ During separate clinical trials, Nivolumab, an existing drug sold as Opdivo and cabozantinib offered better results compared to traditional ©treatments for renal cell cancer patients .//
The research note informed .// .// .// .// .//